Neurologic disorders incidence in HIV+ vs HIV-men Multicenter AIDS Cohort Study, 1996-2011

Neurology

Volumn 79, Issue 18, 2012, Pages 1873-1880

  Mateen, Farrah J ^a,b   Shinohara, Russell T ^c   Carone, Marco ^d   Miller, Eric N ^e   McArthur, Justin C ^a   Jacobson, Lisa P ^b   Sacktor, Ned ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGED; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; EPILEPSY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MORTALITY; MULTICENTER STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SEIZURE; UNITED STATES;

EID: 84871332723     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318271f7b8     Document Type: Article

References (26)

1. UNAIDS. UNAIDS report on the global AIDS epidemic 2010. Available at: http://www.unaids.org/en/dataanalysis/. Accessed April 28, 2012.
2. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011;155:209-216.
3. Wada N, Jacobson LP, Cohen M, et al. Cause-specific life expectancies after age 35 for HIV-infected and HIVnegative individuals followed simultaneously in long-term cohort studies: 1984-2008. Am J Epidemiol (in press 2012).
4. Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994; 44:1892-1900.
5. Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001;56:257-260.
6. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987;126:310-318.
7. Detels R, Jacobson L, Margolick J, et al. The Multicenter AIDS Cohort Study, 1983 to. Public Health 2012;126: 196-198.
8. American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection: report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:778-785.
9. Jacobson LP, Li R, Phair J, et al. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarkerbased equivalence of disease progression. Am J Epidemiol 2002;155:760-770.
10. Liang KY, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
11. Smith RD, Delpech VC, Brown AE, Rice BD. HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS 2010;24:2109-2115.
12. Centers for Disease Control and Prevention (CDC). HIV testing among men who have sex with men: 21 cities, United States, 2008. MMWR Morb Mort Wkly Rep 2011;60:694-699.
13. Centers for Disease Control and Prevention (CDC). HIV surveillance: United States, 1981-2008. MMWR Morb Mort Wkly Rep 2011;60:21:689-693.
14. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008;300:520-529.
15. Heaton RK, Clifford DB, Franklin DR Jr., et al. HIVassociated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010;75:2087-2096.
16. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 2010;67:699-714.
17. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007;21:1915-1921.
18. d'Arminio Monforte A, Cinque P, Mocroft A, et al; Euro- SIDA Study Group. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004;55:320-328.
19. Vivithanaporn P, Heo G, Gamble J, et al. Neurologic disease burden in treated HIV/AIDS predicts survival. Neurology 2010;75:1150-1158.
20. Wright E, Brew BA, Arayawichanont A, et al. Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology 2008;71:50-56.
21. Yoritaka A, Ohta K, Kishida S. Prevalence of neurological complications in Japanese patients with AIDS after the introduction of HAART. Rinsho Shinkeigaku 2007;47: 491-496.
22. Wojna V, Skolasky RL, Hechavarría R, et al. Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol 2006;12:356-364.
23. Oshinaike OO, Okubadejo NU, Ojini FI, Danesi MA. The clinical spectrum of neurological manifestations in HIV/AIDS patients on HAART at the Lagos University Teaching Hospital, Lagos, Nigeria. Nig Q J Hosp Med 2009;19:181-185.
24. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 2004;63:822-827.
25. Cherry CL, Affandi JS, Imran D, et al. Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology 2009;73:315-320.
26. Becker JT, Maruca V, Kingsley LA, et al Multicenter AIDS Cohort Study. Factors affecting brain structure in men with HIV disease in the post-HAART era. Neuroradiology 2012;54:113-121.